Vaccine Pharmacology
Vaccine types, adjuvant mechanisms, immune response kinetics, mRNA platform technology, and pharmacological principles underlying vaccination.
## Principles of Vaccination
Vaccines exploit immunological memory to generate protective immunity without causing disease. They present antigens to the adaptive immune system, inducing B-cell (antibody) and T-cell (cellular) responses. Upon subsequent pathogen encounter, memory cells mount rapid, high-affinity responses that prevent or attenuate disease.
The pharmacology of vaccines encompasses antigen design, adjuvant selection, delivery route, dosing schedule, and storage requirements.
## Vaccine Platforms
**Live attenuated vaccines** (MMR, varicella, yellow fever) use weakened pathogens that replicate limitedly, generating robust humoral and cellular immunity. Contraindicated in immunocompromised patients.
**Inactivated vaccines** (hepatitis A, influenza) use killed whole pathogens. They produce primarily antibody responses and typically require multiple doses and boosters.
**Subunit/protein vaccines** (hepatitis B, HPV, shingles-Shingrix) contain purified antigens. They are safe in immunocompromised patients but require adjuvants for adequate immunogenicity.
**mRNA vaccines** (COVID-19 Pfizer-BioNTech, Moderna) deliver lipid nanoparticle-encapsulated mRNA encoding the target antigen. Host cells translate the mRNA into protein, which is processed and presented via MHC class I and II, eliciting both antibody and cytotoxic T-cell responses. The mRNA is degraded within days.
**Viral vector vaccines** (COVID-19 J&J/AstraZeneca, Ebola) use replication-deficient adenoviruses to deliver antigen-encoding DNA. Pre-existing immunity to the vector can reduce effectiveness.
## Adjuvants
Adjuvants enhance vaccine immunogenicity by activating innate immunity at the injection site. Key adjuvants include:
- **Aluminum salts** (alum): Most widely used. Create antigen depot and activate NLRP3 inflammasome
- **AS01** (Shingrix): MPL + QS-21 in liposomes. Potent T-cell response induction
- **AS04** (Cervarix): MPL + alum. TLR4 agonist activity
- **MF59** (some influenza): Squalene oil-in-water emulsion. Enhances antigen uptake by APCs
## Immune Response Kinetics
Primary vaccination induces a lag phase (5-7 days), followed by IgM production, then IgG class switching. Peak antibody titers occur at 2-4 weeks. Booster doses drive affinity maturation in germinal centers, producing higher-affinity IgG and expanding memory B-cell populations. This is why multi-dose schedules with appropriate intervals (typically 4-8 weeks) are pharmacologically essential.
## Special Populations
Immunocompromised patients may have diminished vaccine responses. Live vaccines are generally contraindicated. Higher doses or additional boosters may be needed (e.g., double-dose hepatitis B in dialysis patients). Timing vaccines relative to immunosuppressive therapy is critical -- ideally 2-4 weeks before initiating B-cell depleting agents.
## Key Takeaways
- mRNA vaccines induce both humoral and cellular immunity via endogenous antigen expression
- Adjuvants activate innate immunity to amplify adaptive responses
- Booster doses drive affinity maturation and long-lived memory cell expansion
- Live vaccines are contraindicated in immunocompromised patients